Container Closure Systems for Intravenous Medications: A Rigorous Evaluation of Best Manufacturing Practices and Patient Safety in Canada, the USA, and the EU.

As pharmaceutical technology evolves, CCS are continually refined, resulting in increasingly robust, efficient, and customized solutions that address the changing demands of drug development and manufacturing. Regulatory bodies like Health Canada, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) impose rigorous standards, though their approaches vary. Health Canada focuses on risk-based evaluations, the FDA emphasizes detailed stability and material testing, and the EMA prioritizes harmonized standards across Europe, collectively ensuring patient safety on a global scale.